A Giannantoni

A Giannantoni

Auto-generated profile, based on publicly available information

A Giannantoni

Department of Urology, University of Perugia, Perugia, Italy

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in European Urology
Verified
Journal Article
Open access
GNGiacomo Novara
Giacomo Novara
WAWalter Artibani
Walter Artibani
MBMatthew D. Barber
Matthew D. Barber
CCChristopher R. Chapple
Christopher R. Chapple
ECElisabetta Costantini
Elisabetta Costantini
DWDavid Waltregny
David Waltregny
Burch colposuspension, pubovaginal sling, and midurethral retropubic tape (RT) and transobturator tape (TOT) have been the most popular surgical treatments for female stress urinary incontinence (SUI). Several randomized controlled trials (RCTs) have been published comparing the different techniques, with conflicting results. Our aim was to evaluate the efficacy, complication, and reoperation rates of midurethral tapes compared with other surgical treatments for female SUI. A systematic review of the literature was performed using the Medline, Embase, Scopus, Web of Science databases, and Cochrane Database of Systematic Reviews. Thirty-nine RCTs were identified. Patients receiving midurethral tapes had significantly higher overall (odds ratio [OR]: 0.61; confidence interval [CI]: 0.46-0.82; p=0.00009) and objective (OR: 0.38; CI: 0.25-0.57; p<0.0001) cure rates than those receiving Burch colposuspension, although they had a higher risk of bladder perforations (OR: 4.94; CI: 2.09-11.68; p=0.00003). Patients undergoing midurethral tapes and pubovaginal slings had similar cure rates, although the latter were slightly more likely to experience storage lower urinary tract symptoms (LUTS) (OR: 0.31; CI: 0.10-0.94; p=0.04) and had a higher reoperation rate (OR: 0.31; CI: 0.12-0.82; p=0.02). Patients treated with RT had slightly higher objective cure rates (OR: 0.8;CI: 0.65-0.99; p=0.04) than those treated with TOT; however, subjective cure rates were similar, and patients treated with TOT had a much lower risk of bladder and vaginal perforations (OR: 2.5; CI: 1.75-3.57; p<0.00001), hematoma (OR: 2.62; CI: 1.35-5.08; p=0.005), and storage LUTS (OR: 1.35; CI: 1.05-1.72; p=0.02). Meta-analysis demonstrated similar outcomes for TVT-O (University of Liège, Liège, Wallonia, Belgium) and Monarc (AMS, Minnetonka, MN, USA). Patients treated with RT experienced slightly higher continence rates than those treated with Burch colposuspension, but they faced a much higher risk of intraoperative complications. RT and pubovaginal slings were similarly effective, although patients with pubovaginal slings were more likely to experience storage LUTS. The use of RT was followed by objective cure rates slightly higher than TOT, but subjective cure rates were similar. TOT had a lower risk of bladder and vaginal perforations and storage LUTS than RT. The strength of these findings is limited by the heterogeneity of the outcome measures and the short length of follow-up.

1 November 2007 in European Urology
Verified
Journal Article
Closed access
MPMassimo Porena
Massimo Porena
ECElisabetta Costantini
Elisabetta Costantini
BFBruno Frea
Bruno Frea
AGAntonella Giannantoni
Antonella Giannantoni
SRStefania Ranzoni
Stefania Ranzoni
EKErvin Kocjancic
Ervin Kocjancic

1 February 2014 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
PDF file
MFMaria Teresa Filocamo
Maria Teresa Filocamo
Maurizio SeratiMaurizio Serati
Maurizio Serati
Vincenzo Li MarziVincenzo Li Marzi
Vincenzo Li Marzi
ECElisabetta Costantini
Elisabetta Costantini
MMMartina Milanesi
Martina Milanesi
DVDonata Villari
Donata Villari

1 July 2004 in Journal of Urology
Verified
Journal Article
Closed access
PDF file
AGAntonella Giannantoni
Antonella Giannantoni
SSSavino M. DI Stasi
Savino M. DI Stasi
RSRobert L. Stephen
Robert L. Stephen
VBVittorio Bini
Vittorio Bini
ECElisabetta Costantini
Elisabetta Costantini
MPMassimo Porena
Massimo Porena
We investigated the effectiveness and safety of intravesical resiniferatoxin (Sigma Chemical Co., St. Louis, Missouri) and botulinum-A toxin injections into the detrusor muscle in a group of spinal cord injured patients with neurogenic detrusor overactivity unresponsive to conventional anticholinergic therapy. A total of 25 patients were randomly assigned to receive intravesically 0.6 μM resiniferatoxin in 50 ml of 0.9% NaCl or injections into the detrusor muscle of 300 units botulinum A-toxin diluted in 30 ml 0.9% NaCl. Clinical evaluation and urodynamics were performed at baseline, and at 6, 12 and 18 months after treatment. In both arms there was a significant decrease in catheterization and incontinent episodes, and a significant increase in first detrusor contraction and maximum bladder capacity at 6, 12 and 18-month followup. There were no local side effects with either treatment. Botulinum-A toxin induced a significant decrease in the frequency of daily incontinence episodes (p <0.05), a significant increase in first uninhibited detrusor contraction (p <0.01) in maximum bladder capacity (p <0.01), and a significant decrease in maximum pressure of uninhibited detrusor contractions (p <0.01) compared to resiniferatoxin at 6, 12 and 18-month followup. In spinal cord injured patients with refractory neurogenic detrusor overactivity, intravesical resiniferatoxin and botulinum-A toxin injections into the detrusor muscle provided beneficial clinical and urodynamic results with decreases in detrusor overactivity and restoration of urinary continence in a large proportion of patients. Botulinum-A toxin injections provided superior clinical and urodynamic benefits compared to those of intravesical resiniferatoxin.

1 April 2006 in European Urology
Verified
Journal Article
Closed access
AGAntonella Giannantoni
Antonella Giannantoni
ECElisabetta Costantini
Elisabetta Costantini
SSSavino M. Di Stasi
Savino M. Di Stasi
MTMaria Cristina Tascini
Maria Cristina Tascini
VBVittorio Bini
Vittorio Bini
MPMassimo Porena
Massimo Porena

1 March 2008 in Journal of Urology
Verified
Journal Article
Closed access
AGAntonella Giannantoni
Antonella Giannantoni
MPMassimo Porena
Massimo Porena
ECElisabetta Costantini
Elisabetta Costantini
AZAlessandro Zucchi
Alessandro Zucchi
LMLuigi Mearini
Luigi Mearini
EMEttore Mearini
Ettore Mearini
We evaluated the 1-year efficacy and tolerability of botulinum A toxin intravesically injected in patients with painful bladder symptoms associated with increased urinary frequency, refractory to conventional treatments. Three men and 12 women were prospectively included in the study. Under short general anesthesia the patients were given injections of 200 U commercially available botulinum A toxin diluted in 20 ml 0.9% NaCl. Injections were performed submucosally in the bladder trigone and lateral walls under cystoscopic guidance. A voiding chart and the visual analog scale for pain were used, and urodynamics were performed before treatment, and 1, 3, 5 and 12 months later. Overall 13 patients (86.6%) reported subjective improvement at the 1 and 3-month followups. The mean visual analog scale score, and daytime and nighttime urinary frequency were significantly decreased (p <0.05, <0.01 and <0.05, respectively). At the 5-month followup the beneficial effects persisted in 26.6% of cases but increased daytime and nighttime urinary frequency, and an increased visual analog scale score were observed compared to baseline. At 12 months after treatment pain recurred in all patients. Nine patients complained of dysuria 1 month after treatment. Dysuria persisted in 4 cases at the 3-month followup and in 2 at the 5-month followup. Intravesically injected botulinum toxin A is effective for short-term management of refractory painful bladder syndrome. The beneficial effects decreased progressively within a few months after treatment. Thus, repeat injections of the neurotoxin are required for efficacious treatment in patients with the disease.